Deaths in MP from spurious cough syrups expose regulatory lapses

The cough syrup tragic incident in MP reportdly claiming 14 lives took it's toll with removal of Dr. Praveen Soni, a paediatric specialist at the Civil Hospital in the Parasia sub-division in Chhindwara district, accused of prescribing the adulterated syrup Coldrif to many of the deceased children at his private clinic by state government on Monday.The state govt has tightened its noise over others allegedly involved in supplier of contaminated syrup. One toddler 15 months including 13 other died after consuming the cough syrup,in Pipariya,MP. CM Dr Mohan Yadav took stock of situation and personally consoled the  beread families and announced exgratia amount of Rs 4 lakh each to the families of 14 deceased children each on Monday.The tragedy, involving Coldrif syrup, underscores how regulatory oversight and accountability continue to fail in one of the world’s largest pharmaceutical markets.Laboratory tests revealed that the syrup contained 48.6% diethylene glycol (DEG) a toxic industrial solvent used in antifreeze and brake fluids far exceeding the World Health Organization’s (WHO) permissible limit of 0.10%. The syrup had been prescribed to children suffering from common colds and coughs. Following the deaths, the Madhya Pradesh government banned the syrup and arrested a doctor who had prescribed it. However, officials admit that they remained unaware of the contamination for several weeks, even as more children fell sick  a stark reminder of weak pharmacovigilance and delayed response.
The incident is not an isolated one. Similar mass poisoning incidents linked to Indian-made syrups have occurred in recent years  from The Gambia and Uzbekistan in 2022, where nearly 150 children died, to Cameroon in 2023 and Jammu and Kashmir in 2020. Each case revealed a disturbing pattern of systemic regulatory failures and poor enforcement of manufacturing standards,according to information.India, often described as the “pharmacy of the world”, supplies 40% of generic drugs used in the United States and over 90% of medicines in many African nations. Yet, the country’s regulatory system remains uneven, particularly in monitoring small and medium-scale drug manufacturers. According to data from the Central Drugs Standard Control Organisation (CDSCO), 36% of inspected manufacturing units were shut down in 2023–24 for serious violations but hundreds of others continue to operate without rigorous oversight.
Experts note that state-level drug regulators lack adequate staff, resources, and autonomy, with inspectors often burdened by administrative work rather than technical audits. Mandatory data on manufacturing practices, inspection results, and safety alerts are poorly maintained, while testing mechanisms for contaminants like DEG are inconsistent.The latest tragedy also raises concerns about compliance with Good Manufacturing Practices (GMP). Many pharmaceutical units are still not registered under the revised GMP norms, despite multiple deadline extensions by the Union government. This non-compliance, coupled with weak testing and enforcement, creates fertile ground for adulteration and negligence.According to information,the Union Health Ministry has now ordered inspections of drug manufacturing units across six states, while states like Karnataka have imposed stricter checks on the sale and use of cough syrups for children. However, questions remain over accountability. The arrest of the doctor who prescribed Coldrif has sparked protests from the Indian Medical Association (IMA), which alleges that the physician has been scapegoated while the manufacturer remains unpunished.Public health experts reportedly noted that the root cause lies in the collapse of regulatory vigilance not just in Madhya Pradesh, but nationwide. Despite repeated international warnings and WHO alerts following earlier incidents, systemic reform has been slow, and offenders have often escaped with minimal consequences.